Literature DB >> 18063073

Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery.

Alexandra I Stavrakis1, Philip H G Ituarte, Clifford Y Ko, Michael W Yeh.   

Abstract

BACKGROUND: Surgeon experience correlates with improved outcomes for complex operations. Endocrine operations are increasingly performed in the outpatient setting, where outcomes have not been systematically studied. We examined the effect of surgeon volume on clinical and economic outcomes for thyroid, parathyroid, and adrenal surgery across inpatient and outpatient settings.
METHODS: New York and Florida state discharge data (2002) were studied. Surgeons were grouped by annual endocrine operative volume: Group A, 1 to 3 operations; B, 4 to 8; C, 9 to 19; D, 20 to 50; E, 51 to 99; and F, >or=100. Multiple regression analyses were applied to analyze complications, length of stay (LOS), and total charges (TC), while controlling for comorbidity, economic factors, and hospital-centric variables.
RESULTS: We identified 13,997 discharges, with 28% of operations performed on an outpatient basis (admission/discharge on same calendar day). For all cases, group A contributed disproportionately more complications (observed/expected [O/E] 1.65, P < .001) and Group F contributed disproportionately less (0.52; P < .001). High surgeon volume was associated with decreased LOS and reduced TC. Hospital volume had a negligible effect on outcomes.
CONCLUSIONS: Surgeon volume correlates inversely with complication rates, LOS, and TC, in endocrine surgery. The lowest complication rates are achieved by surgeons performing >or=100 endocrine operations annually.

Entities:  

Mesh:

Year:  2007        PMID: 18063073     DOI: 10.1016/j.surg.2007.09.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  82 in total

1.  [Current thyroid and parathyroid surgery].

Authors:  H Dralle
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

Review 2.  Influence of surgical volume on operative failures for hyperparathyroidism.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Adv Surg       Date:  2011

3.  Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients.

Authors:  A Bergenfelz; S Jansson; A Kristoffersson; H Mårtensson; E Reihnér; G Wallin; I Lausen
Journal:  Langenbecks Arch Surg       Date:  2008-07-17       Impact factor: 3.445

4.  Remedial operation for primary hyperparathyroidism.

Authors:  Jason D Prescott; Robert Udelsman
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

5.  Informal regionalization of pediatric fracture care in the Greater Toronto Area: a retrospective cross-sectional study.

Authors:  Daniel Pincus; Steven Morrison; Martin F Gargan; Mark W Camp
Journal:  CMAJ Open       Date:  2017-06-14

6.  Mortality after thyroid surgery, insignificant or still an issue?

Authors:  Joaquín Gómez-Ramírez; Antonio Sitges-Serra; Pablo Moreno-Llorente; Antonio Ríos Zambudio; Joaquín Ortega-Serrano; María Teresa Gutiérrez Rodríguez; Jesús Villar del Moral
Journal:  Langenbecks Arch Surg       Date:  2015-04-23       Impact factor: 3.445

Review 7.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

Review 8.  [Vocal cord paralysis after thyroid surgery : Current medicolegal aspects of intraoperative neuromonitoring].

Authors:  H Dralle; R Schneider; K Lorenz; N Thanh Phuong; C Sekulla; A Machens
Journal:  Chirurg       Date:  2015-07       Impact factor: 0.955

9.  [Fewer complications with more than six adrenalectomies per year].

Authors:  H Dralle
Journal:  Chirurg       Date:  2019-03       Impact factor: 0.955

10.  Should total thyroidectomies be performed by high-volume endocrine surgeons? A cost-effectiveness analysis.

Authors:  Panagiotis Anagnostis; Ioannis Pliakos; Stavros Panidis; Angeliki Chorti; Veronika Stelmach; Antonios Michalopoulos; Theodosios S Papavramidis
Journal:  Endocrine       Date:  2019-09-20       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.